Live tape
Top 8, mentions 7d14,338NVDA4,854 mentions▲ +0.04GOOGL2,061 mentions▲ +0.04SPY1,736 mentions▲ +0.06QQQ1,554 mentions▲ +0.05AMD1,212 mentions▲ +0.08SPCX1,106 mentions▲ +0.05TSLA954 mentions▲ +0.04SNDK861 mentions▲ +0.05

Equity · Healthcare

LXEO

NASDAQ

Lexeo Therapeutics (LXEO)

4.68 USD +3.08% vs prior close
Lexeo Therapeutics, Inc. price graph

This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers.

Track this symbol on TradingView
Market cap
384.0M USD
EPS, diluted, year to Dec 2025
−1.86 USD
52-week range
3.67 USD – 10.63 USD
Avg volume
230.1K

as of Jul 17, 2026

Have Lexeo Therapeutics (LXEO) insiders bought or sold shares recently?

In the 90 days to 10 Nov 2026, Lexeo Therapeutics insiders reported 3 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 15 Oct 2025, show no open-market purchase.

Form 4, 90 days to 10 Nov 2026, newest reported trade 18 Aug 2026

0buys
3sells
$43Knet sold
3other filings
Have Lexeo Therapeutics (LXEO) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
18 Aug 2026Townsend Richard NolanChief Executive OfficerSell3,34517K USD
18 Aug 2026Otero Jose ManuelChief Operating OfficerSell1,3046K USD
18 Aug 2026Tamayo Louis EdwardChief Financial OfficerSell4,11720K USD
Sold3 open-market sales8,766$43K
3 other filings in the window: grants, exercises, tax withholding and transfers, not trades
Have Lexeo Therapeutics (LXEO) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
14 Sep 2026Bhalla Narinder PalChief Medical OfficerAward2,71410K USD
14 Sep 2026Townsend Richard NolanChief Executive OfficerAward2,3066K USD
14 Sep 2026Otero Jose ManuelChief Operating OfficerAward2,1106K USD

Which funds hold Lexeo Therapeutics (LXEO)?

1 of the 45 institutional funds we track reported a Lexeo Therapeutics position for the quarter ended 30 Sep 2026 — a combined 386K USD; the latest of those filings landed 06 Nov 2026.

Form 13F

Which funds hold Lexeo Therapeutics (LXEO)?
FundPositionSharesValueShares q/q
Fisher Asset ManagementHeld (±25%)114,322386K USD

What has been filed or recorded for Lexeo Therapeutics (LXEO)?

The filings we hold for Lexeo Therapeutics, newest first: 5 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 4 reported financial figures, the latest dated 13 Oct 2026. No next earnings date is announced in SEC filings yet.

What has been filed or recorded for Lexeo Therapeutics (LXEO)?
And
13 Oct 2026Fails to deliverShares failed to deliver6,471 shares20K USD notional · 0.008% of shares out
09 Oct 2026Fails to deliverShares failed to deliver1,933 shares6K USD notional · 0.002% of shares out
02 Oct 2026Fails to deliverShares failed to deliver522 shares2K USD notional · 0.001% of shares out
01 Oct 2026Fails to deliverShares failed to deliver2,500 shares8K USD notional · 0.003% of shares out
29 Sep 2026Fails to deliverShares failed to deliver9 shares28 USD notional · <0.001% of shares out
30 Jun 2026Quarterly earningsQ2 2026 reportedEPS −0.30 USD
30 Jun 2026FinancialsTotal assets254.9M USDat period end
30 Jun 2026FinancialsTotal equity235.1M USDat period end
31 Mar 2026Quarterly earningsQ1 2026 reportedEPS −0.25 USD
31 Dec 2025Annual reportFY 2025 reportedEPS −1.86 USD
31 Dec 2025FinancialsNet income−100.0M USDfiscal year
31 Dec 2025FinancialsDiluted EPS−1.86 USDfiscal year
30 Sep 2025Quarterly earningsQ3 2025 reportedEPS −0.33 USD
30 Jun 2025Quarterly earningsQ2 2025 reportedEPS −0.60 USD
31 Mar 2025Quarterly earningsQ1 2025 reportedEPS −0.99 USD
31 Dec 2024Annual reportFY 2024 reportedEPS −3.09 USD
30 Sep 2024Quarterly earningsQ3 2024 reportedEPS −0.89 USD

What do people ask about Lexeo Therapeutics (LXEO)?

From live data
What is Lexeo Therapeutics’ market cap?384.0M

Lexeo Therapeutics is worth 384.0M USD by market value as of 17 Jul 2026, which is the share price times the shares on issue from its SEC filings.

Have Lexeo Therapeutics insiders bought or sold shares recently?3 sales

In the 90 days to 10 Nov 2026, Lexeo Therapeutics insiders reported 3 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 15 Oct 2025, show no open-market purchase. A further 3 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders

Which funds own Lexeo Therapeutics?1 of 45

1 of the 45 funds we track reported a Lexeo Therapeutics position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported position was Fisher Asset Management. See Funds

When did Lexeo Therapeutics last report earnings?−0.30

Lexeo Therapeutics last reported earnings on 30 Jun 2026 for Q2 2026, with EPS of −0.30 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

References
  1. Finazonprior-day close, indicative (IEX-derived, not the official close)
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARForm 4 filings (insider transactions)
  4. SEC EDGAR13F filings
  5. SECSEC fails-to-deliver (CNS) data
  6. SEC EDGARXBRL company facts, latest period ended 30 Jun 2026
  7. SEC EDGARreported earnings figures and scheduled report dates
  8. SEC EDGARValuation computed from SEC EDGAR filings